Koska Juraj, de Courten Barbora, Wake Deborah J, Nair Saraswathy, Walker Brian R, Bunt Joy C, Permana Paska A, Lindsay Robert S, Tataranni P Antonio
Obesity and Diabetes Clinical Research Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Phoenix, AZ 85016, USA.
Obesity (Silver Spring). 2006 Sep;14(9):1515-22. doi: 10.1038/oby.2006.175.
Increased mRNA and activity levels of 11beta-hydroxysteroid dehydrogenase type 1 (11betaHSD1) in human adipose tissue (AT) are associated with obesity and insulin resistance. The aim of our study was to investigate whether 11betaHSD1 expression or activity in abdominal subcutaneous AT of non-diabetic subjects are associated with subsequent changes in body weight and insulin resistance [homeostasis model assessment of insulin resistance (HOMA-IR)].
Prospective analyses were performed in 20 subjects (two whites and 18 Pima Indians) who had baseline measurements of 11betaHSD1 mRNA and activity in whole AT (follow-up, 0.3 to 4.9 years) and in 47 Pima Indians who had baseline assessments of 11betaHSD1 mRNA in isolated adipocytes (follow-up, 0.8 to 5.3 years).
In whole AT, although 11betaHSD1 mRNA levels showed positive associations with changes in weight and HOMA-IR, 11betaHSD1 activity was associated with changes in HOMA-IR but not in body weight. 11betaHSD1 mRNA levels in isolated adipocytes were not associated with follow-up changes in any of the anthropometric or metabolic variables.
Our results indicate that increased expression of 11betaHSD1 in subcutaneous abdominal AT may contribute to risk of worsening obesity and insulin resistance. This prospective relationship does not seem to be mediated by increased 11betaHSD1 expression in adipocytes.
人脂肪组织（AT）中11β-羟基类固醇脱氢酶1型（11βHSD1）的mRNA和活性水平升高与肥胖及胰岛素抵抗相关。我们研究的目的是调查非糖尿病受试者腹部皮下脂肪组织中11βHSD1的表达或活性是否与随后的体重变化及胰岛素抵抗[胰岛素抵抗稳态模型评估（HOMA-IR）]相关。
对20名受试者（2名白人及18名皮马印第安人）进行前瞻性分析，这些受试者有全脂肪组织中11βHSD1 mRNA和活性的基线测量值（随访时间为0.3至4.9年），并对47名皮马印第安人进行了分析，他们有分离脂肪细胞中11βHSD1 mRNA的基线评估值（随访时间为0.8至5.3年）。
在全脂肪组织中，虽然11βHSD1 mRNA水平与体重和HOMA-IR的变化呈正相关，但11βHSD1活性与HOMA-IR的变化相关，而与体重变化无关。分离脂肪细胞中的11βHSD1 mRNA水平与任何人体测量或代谢变量的随访变化均无关联。
我们的结果表明，腹部皮下脂肪组织中11βHSD1表达增加可能会增加肥胖和胰岛素抵抗恶化的风险。这种前瞻性关系似乎并非由脂肪细胞中11βHSD1表达增加所介导。
